CONMED Corporation(CNMD)
USD --+0.00%
Reward62Moderate
Risk42Moderate
📊75%Data
Thin 3% profit margin
CNMD
+0.0 · +0.00%
USD · NYSE
CONMED Corporation | Healthcare
Quality Compounder
Market Cap:1.41Bn
ℹ️
Reward Rating
62
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
42
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on CNMD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $47.40.

What is CONMED Corporation?

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures.

CNMD · Verdict

Solid reward · moderate risk

CNMD scores well on cash flow and growth with no major weaknesses flagged in the model.

Based on 88% data coverage

CNMD · Verdict

What’s working & what to watch

Strengths 2

  • Cash flow74/100

    11% free-cash-flow margin

  • Growth73/100

    Revenue +9.6% CAGR

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is CONMED Corporation?

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 1.41B, and a P/E ratio of 30.1x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (62)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.41B
P/E Ratio30.053
Dividend Yield1.33%
52 Week High64.1695
52 Week Low35.37
Last AnnualDecember
IPO Date7/23/1987
IncorporatedUSA
Shares Outstanding31M
No. of Employees3,900
IndustryMedical Devices
ExchangeNYSE
Beta0.956
CurrencyUSD